The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Stroke, Statins, and Cholesterol: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials With HMG-CoA Reductase Inhibitors
Abstract
Background and Purpose To estimate the effect of 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors (“statins”) on stroke risk, we combined the data of the randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors published so far. Methods The studies were identified using the Medline CD+ and Current Contents databases from January 1980 through May 1996, inclusive. All studies were evaluated on the use of a placebo control, monotherapy, and double blindness. When the type of stroke or the occurrence of clinical events or adverse effects were incompletely or not reported, the investigators were contacted personally. For each trial, the number of strokes in the treatment arm was compared with the number of strokes expected on all observations under the assumption that drug treatment had no effect. Results A total of 462 strokes among 20 438 participants in 13 trials could be analyzed. A total of 181 strokes were observed in patients randomized to treatment with an HMG-CoA reductase inhibitor and 261 strokes in patients randomized to placebo. A lower than expected number of strokes was observed in the treatment groups of all but one trial ( P =.001). Treatment with an HMG-CoA reductase inhibitor led to an overall risk reduction of 31% (odds ratio, 0.69; 95% confidence interval, 0.57 to 0.83). Conclusions The combined data suggest that treatment with HMG-CoA reductase inhibitors prevents stroke in middle-aged persons. Because stroke is especially common in older age, these data reinforce the need for clinical trials to evaluate the effect of HMG-CoA reductase inhibitors in preventing stroke in the elderly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Treasure, C. B., Klein, J. L., Weintraub, W. S., Talley, J. D., Stillabower, M. E., Kosinski, A. S., Zhang, J., Boccuzzi, S. J., Cedarholm, J. C., & Alexander, R. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320801 · Cited by 1,097
&NA; (1996) · Journal of Occupational & Environmental Medicine · doi:10.1097/00043764-199605000-00005 · Cited by 1,070
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 867
(1995) · The Lancet · doi:10.1016/s0140-6736(95)92836-7 · Cited by 856
Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 842
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Endres, M., Laufs, U., Huang, Z., Nakamura, T., Huang, P., Moskowitz, M. A., & Liao, J. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8880 · Cited by 966
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
National Clinical Guidelines for Stroke.
Robinson, T. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.906.286h · Cited by 608
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization
Stoll, G., & Bendszus, M. (2006) · Stroke · doi:10.1161/01.str.0000226901.34927.10 · Cited by 503
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Total cholesterol and risk of mortality in the oldest old
Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knock, D. L., Meinders, A. E., & Westendorp, R. G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04430-9 · Cited by 474
Self-citationGorelick, P. B., Sacco, R. L., Smith, D. B., Alberts, M., Mustone-Alexander, L., Rader, D., Ross, J. L., Raps, E., Ozer, M. N., Brass, L. M., et al. (1999) · JAMA · doi:10.1001/jama.281.12.1112 · Cited by 473
The Symptomatic Carotid Plaque
Golledge, J., Greenhalgh, R. M., & Davies, A. H. (2000) · Stroke · doi:10.1161/01.str.31.3.774 · Cited by 450
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Self-citationPlehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.216 · Cited by 429
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Vaughan, C. J., & Delanty, N. (1999) · Stroke · doi:10.1161/01.str.30.9.1969 · Cited by 386
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 373
Pravastatin Therapy and the Risk of Stroke
White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J. D. G., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S., Kirby, A. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430502 · Cited by 338
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Shahar, E., Chambless, L. E., Rosamond, W. D., Boland, L. L., Ballantyne, C. M., McGovern, P. G., & Sharrett, A. R. (2003) · Stroke · doi:10.1161/01.str.0000057812.51734.ff · Cited by 325
Sacco, R. L., Benson, R. T., Kargman, D. E., Boden-Albala, B., Tuck, C., Lin, I.-F., Cheng, J. F., Paik, M. C., Shea, S., & Berglund, L. (2001) · JAMA · doi:10.1001/jama.285.21.2729 · Cited by 311
Statins for the primary prevention of cardiovascular disease
Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 305
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project
Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J. (2001) · Circulation · doi:10.1161/01.cir.103.3.387 · Cited by 276
Bloomfield Rubins, H., Davenport, J., Babikian, V., Brass, L. M., Collins, D., Wexler, L., Wagner, S., Papademetriou, V., Rutan, G., & Robins, S. J. (2001) · Circulation · doi:10.1161/01.cir.103.23.2828 · Cited by 269
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 266
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
Dementia, stroke, and vascular risk factors; a review
Sahathevan, R., Brodtmann, A., & Donnan, G. A. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00731.x · Cited by 230
Weverling-Rijnsburger, A. W. E., Jonkers, I. J. A. M., van Exel, E., Gussekloo, J., & Westendorp, R. G. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1549 · Cited by 199
“Finally, 2 metaanalyses have shown that treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors, known to lower lowdensity lipoprotein (LDL) cholesterol and to increase HDL cholesterol levels, reduces stroke risk by 30%.(8,9) This finding ORIGINAL INVESTIGATION”
BackgroundSelf-citationFavorable Outcome of Ischemic Stroke in Patients Pretreated with Statins
Martí-Fàbregas, J., Gomis, M., Arboix, A., Aleu, A., Pagonabarraga, J., Belvís, R., Cocho, D., Roquer, J., Rodríguez, A., García, M. D., et al. (2004) · Stroke · doi:10.1161/01.str.0000125863.93921.3f · Cited by 192
Kang, S., Wu, Y., & Li, X. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.005 · Cited by 126
Napoli, C., Witztum, J. L., de Nigris, F., Palumbo, G., D’Armiento, F. P., & Palinski, W. (1999) · Circulation · doi:10.1161/01.cir.99.15.2003 · Cited by 110
Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P. (2003) · Angiology · doi:10.1177/000331970305400607 · Cited by 85
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Okumura, K., Iseki, K., Wakugami, K., Kimura, Y., Muratani, H., Ikemiya, Y., & Fukiyama, K. (1999) · Japanese Circulation Journal · doi:10.1253/jcj.63.53 · Cited by 69
Metadata
- Authors
- Blauw, G. J., Lagaay, A. M., Smelt, A. H. M., & Westendorp, R. G. J.
- Venue
- Stroke
- Published
- 1997-05
- Volume
- 28
- Issue
- 5
- Pages
- 946-950
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2007032912
- Cited by
- 311
- References
- 29
- FWCI
- 28.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.